MIP_3b
- Known as:
- MIP_3b
- Catalog number:
- ANT-213
- Product Quantity:
- 500µg
- Category:
- -
- Supplier:
- Prospecbio
- Gene target:
- MIP_3b
Related products to: MIP_3b
Related articles to: MIP_3b
- Triple-negative breast cancer (TNBC) presents a major clinical challenge owing to its immunosuppressive tumor microenvironment, target scarcity, and poor therapeutic response. Recently, the combination therapy of immune checkpoint blockade and CCL19 has shown significant efficacy in TNBC. To systematically unravel the synergistic mechanisms between CCL19 and anti-PD-1, we developed a mathematical model by integrating cellular and molecular scales to capture essential tumor-immune interactions and predict the dynamics of tumor evolution under various therapies. In this study, we proposed three quantitative indicators: (1) the tumor relative volume index (TRVI), (2) the therapeutic efficacy discrepancy index (TEDI), and (3) the immune heterogeneity treatment response index (IHTRI). Our model validated that the immunostimulatory effect of CCL19 in synergizing with anti-PD-1, and revealed that this synergy is highly modulated by individual baseline immune heterogeneity. Notably, our analysis identified (CTLs × CCL19)/PD-L1 as a novel dynamic biomarker combination with significant predictive (AUC = 0.86) and prognostic value (log-rank p= 0.019). Finally, virtual clinical trials revealed that administering anti-PD-1 therapy prior to CCL19 injection draws more significant clinical benefits in TNBC. Collectively, this study provides a theoretical foundation for elucidating the synergistic mechanism between CCL19-mediated immunostimulation and anti-PD-1 therapy. - Source: PubMed
Publication date: 2026/04/16
Gao ChunjieLi ChenghangDu LeiLiu JingLei JinzhiWang Lei - S100A12 as an indispensable molecular components inflammatory cytokines in human physiology. Notably, similar pathological mechanisms involving chronic low-grade inflammation are also observed in intervertebral disc degeneration (IVDD) and osteoporosis (OP), making the interplay between these diseases and inflammatory cytokines indisputable. Nevertheless, the precise identity of cytokines that concurrently fuel IVDD and OP remains elusive, hindering targeted therapeutic strategies. - Source: PubMed
Publication date: 2026/04/09
Wang ZexinChen BinLiu ZhenchuanZhang YuanqiangHan Leixiang - Anti-NMDA receptor (NMDAR) encephalitis is an autoimmune disorder of the central nervous system involving both B- and T-cell activation. In this exploratory study, targeted proteomics was used to characterize protein expression profiles in serum and cerebrospinal fluid (CSF) from patients with anti-NMDAR encephalitis. Samples from eight patients and 16 age- and sex-matched symptomatic controls were analyzed in a retrospective case-control design. Protein concentrations in serum and CSF were quantified using Proximity Extension Assay (PEA) technology targeting 182 proteins related to immunity, synaptic regulation, and neuronal maintenance. Linear regression identified seven significantly altered proteins in CSF and three in serum after Bonferroni correction (p < 0.00027). In CSF, six proteins associated with immune signaling and neuronal support (ADA, CCL19, CXCL5, BMP-4, FGF-5, CDH3) were decreased, while the protease CASP-8 was elevated. In serum, proteases CTSC and CASP-8 were increased, whereas ADA, a key regulator of purine metabolism and immune signaling, was decreased. Strong to moderate correlations between CSF and serum levels were observed for ADA (r = 0.606, p = 0.013) and CASP-8 (r = 0.526, p = 0.037). Longitudinal CSF data from two patients revealed dynamic changes in CXCL5, CCL19, and CASP-8 corresponding to disease activity and treatment response. Overall, these findings revealed distinct yet related proteomic signatures in serum and CSF, suggesting compartment-specific immune responses involving both innate and adaptive pathways. The consistent elevation of CASP-8 highlights its potential as a biomarker of disease activity and warrants further investigation. - Source: PubMed
Publication date: 2026/04/03
Kosek SonjaWiberg AnnaPersson BarbroGabrysch KatjaBurman JoachimPunga Anna Rostedt - Sjögren's Disease (SjD) is a chronic autoimmune condition characterized by lymphocytic infiltration of lacrimal glands (LG) and salivary glands (SG). In SG, these immune structures have properties of ectopic lymphoid structures (ELS) and appear to play a critical role in disease pathology. While the presence of ELS in patients' SG biopsies is linked to disease severity, their presence and composition in LG has not been well characterized. - Source: PubMed
Publication date: 2026/03/19
Abdelhamid SaraRamirez Alison VAksan EmreDemianova Elizaveta Ade Paiva Cintia SEdman Maria CMacKay J AndrewHamm-Alvarez Sarah F - Lupus nephritis (LN) represents the most severe renal manifestation of systemic lupus erythematosus (SLE), contributing to significant morbidity. While current assessments focus on glomerular pathology, tubulointerstitial lesions may offer critical insights into disease progression and treatment response. This study develops a clinical prediction model integrating tubulointerstitial molecular signatures. We performed bioinformatics analysis using two independent tubulointerstitial gene expression datasets (GSE113342 and GSE200306), applying batch effect correction and principal component analysis (PCA) to identify differentially expressed genes (DEGs). A protein‒protein interaction (PPI) network isolated hub genes, and least absolute shrinkage and selection operator (LASSO) regression defined the novel "Nscore" parameter predictive of treatment response. The Nscore, incorporating seven key genes (EGR1, IL6R, TFRC, CCL19, IFI16, IFI35, and Fra1), showed a significant positive correlation with 24-h proteinuria and effectively distinguished complete-response (CR)/partial-response (PR) from non-response (NR). Immune deconvolution using the CIBERSORT algorithm revealed an increased abundance of T follicular helper (Tfh) cells and M1 macrophages in NR samples. A clinical nomogram integrating Nscore and sex demonstrated excellent discrimination. This model combines molecular biomarkers with clinical parameters to improve personalized therapeutic stratification, advancing treatment strategies beyond traditional glomerulocentric paradigms and identifying immune cell signatures as potential targets for immunomodulatory interventions. - Source: PubMed
Publication date: 2026/04/02
Ke JialongGu GuanghongNi WenpengHe JialinZeng ZhouyuLin RunpeiPeng JianmingDeng KunyiWen LijuanChen YanhuiTan NanZhang Chilun